Notice of Participation of the National Cancer Institute (NCI) in RFA-AG-25-004, "Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)"
Notice Number:
NOT-CA-24-049

Key Dates

Release Date:

May 10, 2024

Related Announcements

  • April 24, 2024 - Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required). See NOFO RFA-AG-25-004

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in RFA-AG-25-004, "Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)".
 

The following text (in italics) has been added to reflect NCI's participation in this NOFO:
 

Part 1. Overview Information

Components of Participating Organizations

National Institute on Aging (NIA)
National Center for Complementary and Integrative Health (NCCIH)
National Cancer Institute (NCI)

Assistance Listing Number(s)

93.866, 93.213; 93.393

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description


NCI is particularly interested in projects that include rigorous trials focused on chronic pain in cancer patients. Populations of interest include both older patients currently undergoing cancer treatment or cancer-related palliative care or cancer survivors experiencing chronic pain related to cancer treatment. The pain conditions of interest include cancer-related pain, such as metastatic and bone cancer pain, and treatment-related pain, such as peripheral neuropathy or post-surgical pain. NCI is also particularly interested in trials that target minority older adults and cancer patients with comorbidities that often preclude them from participating in clinical trials.

Part 3. Section VII. Agency Contacts


Scientific/Research Contact(s)

NIA Psychedelic Research
Email: NIAPsychedelicResearch@nih.gov

Sekai Chideya-Chihota, MD, MPH
National Center for Complementary and Integrative Health (NCCIH)
Phone: 240-552-2994
Email: sekai.chideya@nih.gov

Rachel Altshuler, PhD
National Cancer Institute (NCI)
Telephone:240-276-5873Email: rachel.altshuler@nih.gov

Financial/Grants Management Contact(s)

Luchelle Stubbs
Email: luchelle.stubbs@nih.gov

Debbie Chen
National Center for Complementary and Integrative Health (NCCIH)
Phone: 301-594-3788
Email: debbie.chen@nih.gov

Crystal Wolfrey
National Cancer Institute
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

All other aspects of RFA-AG-25-004 remain the same.
 

Inquiries

Please direct all inquiries to:

Rachel Altshuler, PhD
National Cancer Institute (NCI)
Telephone:240-276-5873Email: rachel.altshuler@nih.gov